[177Lu]-DOTA-IAB-2

N/A

Report date: 2025/10/20 14:43:36

Base Information

Drug Name[177Lu]-DOTA-IAB-2

Drug Alias Name[177Lu]-DOTA-IAB-2

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImaginab Inc

China Registration ClassN/A

Develop Information

Active CompaniesImaginab Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A